Meeting Coverage
PW spoke with Anat Shani, Synchrony Medical, who shared insights into how airway clearance therapy is evolving in COPD.
CHEST 2025 studies highlight new COPD research showing improved symptoms, quality of life, and reduced steroid use.
CHEST 2025 marks 90 years of the American College of Chest Physicians with new advances in pulmonary and critical care.
TP53 mutations drive resistance and lower survival in ALK-rearranged lung cancer with distinct RB1 co-mutation effects.
This year’s meeting takes place from November 7th through November 11th at the Walter E. Washington Convention Center.
Global experts will unveil advances in cancer prevention, diagnosis, and treatment at ESMO 2025, Oct 17–21 in Berlin.
A recent study revealed ALK+ NSCLC patients face psychological, professional, and lifestyle challenges despite longer surviva
The meeting is expected to bring together leading hepatology experts to explore the evolving landscape of treatment for MASH.
WCLC included abstracts on metastatic non-small cell lung cancer focused on antibody-drug conjugate and cytotoxic therapy.
By targeting the molecules that cancer cells need to proliferate, these treatments cause less damage to healthy cells.
New data on non-small cell lung cancer (NSCLC) were presented at the 2025 ASCO Annual Meeting earlier this year.
At the 2025 ASCO Annual Meeting, researchers and clinicians highlighted strategies to improve outcomes in NSCLC.
Researchers created a clinicopathologic relapse risk score and linked it with AI-derived immune signatures.
Identifying reliable biomarkers to predict therapeutic benefit remains a critical unmet need.
Exhaled breath analysis has emerged as a noninvasive tool with potential diagnostic and predictive applications in oncology.
Stereotactic body radiation therapy is the standard of care for patients with medically inoperable stage I/II NSCLC.
Patients treated with chemotherapy experienced the highest 3-year overall survival, followed by chemoimmunotherapy.
This quiz explores how cholesterol levels, genetic factors, and related conditions like kidney disease influence CVD risk.
Researchers at the 2025 ASCO Annual Meeting presented several new studies on small cell lung cancer testing and treatment.
Researchers at the 2025 ASCO Annual Meeting identified barriers and solutions to biomarker testing uptake in NSCLC.
180 Mount Airy Road Suite 205
Basking Ridge, NJ 07920
Connect
The content of this site is intended for healthcare professionals.
© 2025 Physician’s Weekly, a Formedics PropertyAny views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Physician’s Weekly, their employees, and affiliates.